| scholarly article | Q13442814 |
| P2093 | author name string | P S Parfrey | |
| D C Murray | |||
| J D Harnett | |||
| R N Foley | |||
| B F Culleton | |||
| G M Kent | |||
| P E Barre | |||
| P2860 | cites work | Outcome of renal replacement treatment in patients with diabetes mellitus | Q35170665 |
| How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects | Q35187942 | ||
| Left ventricular function in diabetes mellitus. I: Methodology, and prevalence and spectrum of abnormalities | Q36778735 | ||
| Left ventricular function in diabetes mellitus. II: Relation between clinical features and left ventricular function | Q36778779 | ||
| Diabetes and cardiovascular disease. The Framingham study | Q41509493 | ||
| Role of diabetes in congestive heart failure: the Framingham study | Q44758886 | ||
| The prognostic importance of left ventricular geometry in uremic cardiomyopathy | Q45009177 | ||
| Race and diabetes as death risk predictors in hemodialysis patients | Q46494130 | ||
| End-stage renal disease attributable to diabetes mellitus | Q46592049 | ||
| Usefulness of left ventricular size and function in predicting survival in chronic dialysis patients with diabetes mellitus | Q47408286 | ||
| Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. | Q50596876 | ||
| Demography and survival of patients receiving treatment for chronic renal failure in Australia and New Zealand: report on dialysis and renal transplantation treatment from the Australia and New Zealand Dialysis and Transplant Registry. | Q50597792 | ||
| Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. | Q50614527 | ||
| Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. | Q50614739 | ||
| Screening diabetic transplant candidates for coronary artery disease: identification of a low risk subgroup. | Q52391463 | ||
| Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. | Q52429603 | ||
| A multicenter, selection-adjusted comparison of patient and technique survivals on CAPD and hemodialysis | Q53924251 | ||
| Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study) | Q57604699 | ||
| Continuous ambulatory peritoneal dialysis and hemodialysis: comparison of patient mortality with adjustment for comorbid conditions | Q64112719 | ||
| Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure | Q67522122 | ||
| A new classification of left ventricular geometry in patients with cardiac disease based on M-mode echocardiography | Q67546905 | ||
| Prevalence of, and risk factors for, angiographically determined coronary artery disease in type I-diabetic patients with nephropathy | Q67597556 | ||
| Severity of coronary artery disease in young patients with insulin-dependent diabetes mellitus | Q67810134 | ||
| Comparison of survival in continuous ambulatory peritoneal dialysis and hospital haemodialysis: a multicentric study | Q67951307 | ||
| Echocardiographic-determined left ventricular wall characteristics in insulin-dependent diabetic patients | Q67965118 | ||
| Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study | Q70026998 | ||
| Outcome and risk factors for left ventricular disorders in chronic uraemia | Q71164282 | ||
| The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease | Q71270716 | ||
| Outcome and risk factors of ischemic heart disease in chronic uremia | Q71324601 | ||
| Impact of renal transplantation on uremic cardiomyopathy | Q71568627 | ||
| Hypocalcemia, morbidity, and mortality in end-stage renal disease | Q71715176 | ||
| A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis | Q71788752 | ||
| Left Ventricular Volumes and Ejection Fraction by Echocardiography | Q71832824 | ||
| Death risk predictors among peritoneal dialysis and hemodialysis patients: A preliminary comparison | Q71878235 | ||
| Clinical and echocardiographic disease in patients starting end-stage renal disease therapy | Q72192935 | ||
| Renal replacement therapy in Canada: a report from the Canadian Organ Replacement Register | Q72382648 | ||
| Survival and predictors of death in dialysed diabetic patients | Q72616654 | ||
| Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure | Q72681292 | ||
| Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study. The German Study Group Diabetes and Uremia | Q72857157 | ||
| P433 | issue | 11 | |
| P921 | main subject | heart disease | Q190805 |
| P304 | page(s) | 1307-1312 | |
| P577 | publication date | 1997-11-01 | |
| P1433 | published in | Diabetologia | Q5270140 |
| P1476 | title | Cardiac disease in diabetic end-stage renal disease. | |
| P478 | volume | 40 |
| Q88496672 | 1H NMR-based metabolomics approach to investigating the renal protective effects of Genipin in diabetic rats |
| Q73635381 | Advanced glycosylation end products (AGEs), insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) in patients with type 2 diabetes mellitus |
| Q35903486 | Anemia and diabetes. |
| Q36659505 | Anemia and diabetic nephropathy |
| Q37082720 | Association of glomerular filtration rate and inflammation with left ventricular hypertrophy in chronic kidney disease patients |
| Q36245164 | Cardiorenal disease: a clinical intersection |
| Q37877789 | Cardiovascular risk in diabetic end-stage renal disease patients |
| Q38609767 | Chinese medicines in the treatment of experimental diabetic nephropathy. |
| Q37165278 | Cigarette smoking: an important renal risk factor - far beyond carcinogenesis |
| Q46661747 | Cigarette smoking: an important renal risk factor – far beyond carcinogenesis. |
| Q51561318 | Clinical and biochemical characteristics of type 2 diabetic patients on continuous ambulatory peritoneal dialysis: relationships with insulin requirement. |
| Q57649306 | Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes |
| Q37914761 | Clinical impact of albuminuria in diabetic nephropathy |
| Q40553175 | Combined Assessment of Cardiac Systolic Dysfunction and Coronary Atherosclerosis Used to Predict Future Cardiac Deaths after Starting Hemodialysis |
| Q44558885 | Comorbidities and survival of patients with type 1 diabetes on renal replacement therapy |
| Q36310912 | Diabetic nephropathy and anaemia |
| Q57504066 | Echocardiographic evaluation in type 1 diabetic patients on waiting list for isolated pancreas or kidney-pancreas transplantation |
| Q37087913 | Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis |
| Q36636462 | Erythropoiesis-stimulating agents in kidney and cardiac disease |
| Q37253710 | Hemoglobin and overt nephropathy complications in type 1 diabetes |
| Q37205471 | IGF-1 is an independent risk factor for anemia in diabetic pre-dialysis patients |
| Q36480239 | Insulin resistance in diabetic nephropathy--cause or consequence? |
| Q36503235 | Landmark Prediction of Long Term Survival Incorporating Short Term Event Time Information |
| Q45249858 | Long-term prognosis of patients after kidney transplantation: a comparison of those with or without diabetes mellitus |
| Q33542374 | Nephropathy in type 2 diabetes |
| Q37820092 | Oxidative stress in early diabetic nephropathy: fueling the fire |
| Q51755409 | Predictive factors associated with left ventricular hypertrophy at baseline and in the follow-up period in non-diabetic hemodialysis patients. |
| Q33719168 | Preliminary study of hypoxia-related cardiovascular mediator-markers in patients with end-stage renal disease with and without diabetes and the effects of haemodialysis |
| Q35636784 | Smoking in dialysis patients: a systematic review and meta-analysis of mortality and cardiovascular morbidity |
| Q35208122 | The anaemia of silent diabetic nephropathy-prevalence, physiopathology, and management |
| Q57701988 | The contribution of chronic kidney disease to the global burden of major noncommunicable diseases |
| Q34499472 | Treatment of dyslipidemia in patients with type 2 diabetes |
| Q53510308 | rHuEPO dose inversely correlated with the number of circulating CD34+ cells in maintenance hemodialysis patients. |
Search more.